Abstract
Variable expressivity, where individuals carrying identical genetic variants display diverse phenotypes, presents an important challenge in clinical genetics. This is exemplified by the telomere biology disorders (TBDs), which exhibit tremendous clinical heterogeneity despite their presumed monogenic nature, even among individuals harboring the same pathogenic variant. Here, we studied cohorts of patients with TBDs and population biobanks to demonstrate that common genome-wide polymorphisms associated with variation in telomere length in the general population combine with large-effect causal variants to significantly impact TBD expressivity. We go on to show that polygenic variation can contribute to expressivity within a single family with a shared large-effect causal variant, and that common and rare variation converge on a shared set of genes implicated in telomere maintenance. By elucidating the role of common genetic variation in rare disease expressivity in TBDs, these results provide a framework for understanding phenotypic variability in other presumed monogenic disorders.
Competing Interest Statement
V.G.S. is an advisor to Ensoma, unrelated to this work. There are no other relevant declarations to report.
Funding Statement
This work was supported by National Institutes of Health grants R01DK103794, R01HL146500, R01CA265726, R01CA292941 (to V.G.S.), the New York Stem Cell Foundation (to V.G.S.), the Mathers Foundation (to V.G.S.), a gift in memory of Jan Ellen Paradise, MD to Boston Childrens Hospital (to V.G.S.), and the Howard Hughes Medical Institute (to V.G.S.). M.P. was supported by National Institutes of Health grants T32GM007753 and T32GM144273. The work of S.A.S., L.Z., M.R.N, N.G., and L.J.M was supported by the intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board at Boston Children's Hospital gave ethical approval for this work. The institutional review board at the National Cancer Institute gave ethical approval for this work. The Institutional review board at Queen Mary University of London gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵11 Lead contact
Data Availability
The telomere length summary statistics will be deposited at the NHGRI-EBI GWAS catalog upon publication. All code and accompanying de-identified data necessary to reproduce all plots and analyses presented in this study will be deposited at GitHub upon publication. Any additional de-identified data generated in this study are available upon reasonable request to the Lead Contact, provided the request is consistent with study consent documents.
